Challenges of COVID-19 pandemic for dermatology

Uwe Wollina

Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany

Correspondence
Uwe Wollina, Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital, Friedrichstrasse 41, 01067 Dresden, Germany.
Email: uwollina@gmail.com

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus responsible for the pandemic named coronavirus disease 2019 (COVID-19). The disease causes SARS with a significant morbidity and mortality. We provide a review with a focus on COVID-19 in dermatology. We discuss triage of suspected infectious patients, protection of medical doctors and nurses. We discuss the available data on cutaneous symptoms, although disease-specific symptoms have yet not been observed. COVID-19 is a challenge for the treatment of dermatologic patients, either with severe inflammatory disorders or with skin cancer. The consequences for systemic treatment are obvious but it will be most important to collect the clinical data for a better decision process. Last but not least, education in dermatology for students will not be temporarily possible in the classical settings. COVID-19, although not a skin disease, by itself has an immense impact on dermatology.

KEYWORDS
COVID-19 pandemic, dermatology, SARS-CoV-2

1 | INTRODUCTION

The outbreak of a newly recognized coronavirus in Central China, province Hubei, in December 2019 marked the beginning of a new pandemic named coronavirus disease 2019 (COVID-19). COVID-19 is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is structurally related to two other coronaviruses that caused SARS and Middle East respiratory syndrome. Coronaviruses are enveloped, positive single-stranded large RNA viruses. SARS-CoV-2 belongs to the beta subgroup, which is known to be capable of causing severe disease and fatalities with respiratory and fecal-oral infectivity.1

Among the initial 425 patients with confirmed COVID-19-induced pneumonia, the median age was 59 years. The mean incubation period was 5.2 days, with the 95th percentile of the distribution at 12.5 days. The estimated basic reproduction number R0 was 2.2 for Hubei. The mean interval between outbreak of the disease and hospitalization was 9.1 to 12.5 days.2 Until February 26, 2020, more than 78 000 laboratory-confirmed cases had been recorded in China.3

Additional hot spots of the pandemic are the United States (>500 000), Spain, Italy, and Germany (each with >100 000) registered infections, but the number infections of is increasing worldwide with about 1.8 million cases worldwide on April 12, 2020.4

Mucosal membranes are the major entry point for an infection with the new coronavirus. On biopsies of fresh cases, COVID-19-induced vascular changes have also been demonstrated in internal organs and the skin but not the virus itself.5

Specific cutaneous manifestations of COVID-19 infection, however, have not been described so far.3

2 | PREVENTION OF INFECTION IN DERMATOLOGY

Triage of patients with suspected infection is important at hospitals. The diagnosis of COVID-19 is mainly made on clinical signs such as fever, fatigue, dry cough, pneumonia, headache, diarrhea, hemoptysis, dyspnea, rhinorrhea, and on radiological findings. Laboratory tests can confirm diagnosis.6

The hospital has to reorganize activities in dermatology, with a strict focus on emergency patients and cancer patients for primary tumor surgery. Inpatient beds, outpatient consultations, and staff are...
reduced. Dermatologists support triage of patients in the corona ambulance.7

Persistence of coronaviruses on inanimate surfaces like plastic, metal, or glass had been observed for up to 9 days. Surface disinfection with ethanol (62%-71%), 0.1% sodium hypochlorite, or 0.5% hydrogen peroxide can effectively inactivate these virus particles within 1 minute.8

Doctors and nurses need to be protected. Sanitary masks and goggles reduce the risk of viral transmission. This is in particular of importance in clinical dermatology, since clear dermatological diagnoses can rarely be done from a distance larger than 20 cm. If we think of dermoscopy, the distance will be much smaller. Hand washes and disinfection with alcoholic solutions are part of the preventive measures when dealing with patients in dermatology.9 Enveloped viruses like SARS-CoV-2 respond better to ethanol than propanol. Minimal contact time is 30 seconds. The addition of other antimicrobial compounds to alcoholic hand disinfections does not increase efficacy but may increase the risk of irritant contact dermatitis. Alcoholic hand disinfectants preserve the epidermal barrier better than hand washes with soap.10

Disinfection of the medical staff is recommended before and after direct contact to a patient, before any aseptic procedure, after potential exposure to body fluids, and after direct contact to potentially contaminated items or surfaces.11

Structural and organizational measures are also needed, in particular in hospitals with interdisciplinary activities such as tumor boards, councils, and emergency departments.12

The personal protective equipment, however, can cause skin disorders and/or aggravate preexisting skin disease. Facial inflammatory papules have been noted after prolonged wearing protective goggles. Acne and aggravation of rosacea, seborrheic dermatitis, and facial itching could occur.11,13

The combination of a paper towels with the facial mask has been recommended to reduce moisture when wearing the mask.14 Delayed pressure urticaria is possible after wearing goggles and masks to tight.11 Hyperhidrosis has been reported in two-thirds of Chinese health care workers involved in care for COVID-19 patients.11 This may result in a higher risk for nontyphoid typhoid-bacterial disorders, other bacterial infections, and tinea.15

Intensified handwashing and disinfection can cause irritant contact dermatitis by interrupting the epidermal barrier functions. As in other areas of occupational dermatology, the use of disinfectants alone is better tolerated than the combination of soap and disinfectant. Protective creams before the shift and moisturizers during the day reduce the risk of occupational hand dermatitis.9,11

Protective gloves are part of the personal protection. Hands should be clean, disinfected, and dry before wearing the gloves. Long-term use of gloves can cause hyperhidrosis and hyperhydration of the horny layer. Disturbances of epidermal barrier function, maceration, and erosion of skin are possible consequences. This will also increase the risk for allergic contact dermatitis. After changing gloves, a hand wash is recommended followed by a skin care product.11

A recent study among 542 doctors and nurses of tertiary hospitals involved in COVID-19 patient care in Hubei, China, underlined the dimension of occupational skin diseases. The general prevalence rate of occupational skin damages was 97.0% (526/542) among first-line health care workers. The nasal bridge was the most commonly affected site (83.1%). Cheeks, hands, and forehead were also affected. The risk increased if personal protective equipment was carried over 6 hours. The combination of frequent (>10 times/d) hand hygiene and longer time of gloves wearing lead to an odds ratio of 2.17 for occupational hand dermatitis.12

Another survey among 376 health care workers of university and regional hospitals in the province of Wuhan, China, reported skin problems in 74.5%. Hands were affected in 84.5%, followed by cheeks and nasal bridge. Clinical signs were xerosis, eczematous lesions, and maceration. Despite the increased frequency of handwashing and disinfection, only 22.1% used regularly moisturizers.16

Hot water for hand wash and alkaline soaps increases the risk of occupational hand dermatitis.17

There is an excellent Cochrane Review on interventions for preventing occupational hand dermatitis that can be used as guidance.18 The authors come to the conclusion that moisturizers alone or in combination with barrier creams may result in a significant improved protection in both the short-term and in the long-term perspectives. If this can also reduce the incidence of occupational irritant hand dermatitis remains to be confirmed.

Special guidelines for dermoscopy in the pandemic have been suggested recently. They include reduction of dermoscopy in dermatology practice, selection of patients, disinfection of body area and dermatoscope, patient and doctor wearing facial masks, and protective covers for the dermatoscope.19

3 | GENERALIZED CUTANEOUS ERUPTIONS WITH FEVER AND OTHER CUTANEOUS MANIFESTATIONS

It has been shown that cancer patients and patients under immunosuppression belong to a high-risk group for COVID-19. These are patients with a variety of medical drugs that may induce generalized drug eruptions. COVID-19 patients may be treated with antibiotics and antiviral substances that may cause drug eruptions as well. Drug-related eosinophilia with systemic symptoms is an important differential diagnosis.20 Furthermore, several viral infections like measles, dengue fever, rubella can cause generalized cutaneous eruptions with fever.21 Zhang et al22 reported that lymphopenia (75.4%) and eosinopenia (52.9%) were observed commonly among their 140 patients. Drug hypersensitivity (11.4%) and urticaria (1.4%) were the most frequent cutaneous symptoms.22

A report from Italy found cutaneous symptoms in 18 of 88 patients in intensive care unit (ICU) such as erythematous rash (n = 14), widespread urticaria (n = 3), and chickenpox-like vesicles (n = 1).23 In this investigation, no confirmation of diagnosis by
since doses increase the risk of respiratory infections in general.30,31 However, seems to be somewhat increased with infliximab and its biosimilars. In \( \alpha \) seems to be higher with inhibitors of tumor necrosis factor alpha (TNF-\( \alpha \)).13 Among the biologicals, the theoretical risk of COVID-19 infection seems to be higher with inhibitors of tumor necrosis factor alpha (TNF-\( \alpha \)) compared to interleukin (IL) inhibitors. Among the TNF-\( \alpha \), the risk seems to be somewhat increased with infliximab and its biosimilars. In general, TNF-\( \alpha \) is not recommended during infectious disease.29

Ustekinumab, risankizumab, ixekizumab, and brodalumab do not increase the risk of respiratory infections in general.30,31 However, the data should be interpreted with caution, since we do not have the data for COVID-19 yet. There are reports on drug-induced interstitial lung disease by infliximab, adalimumab, and ustekinumab.32 Patients with preexistent pulmonary problems have a higher risk for COVID-19.

IL-17 plays an important role in mucosal protection against bacteria and fungi by the recruitment of neutrophils and induction of antimicrobial peptides. Ablertoer expression of IL-17 is associated to cystic fibrosis, pulmonary hypersensitivity, asthma, and lung fibrosis.33 It has been demonstrated that two other SARS viruses, that is, human betacoronavirus 2c Erasmus Medical Center (HCoV-EMC) and SARS-Cov, upregulate the IL-17-related pathway in lung epithelial cells.34 Theoretically, IL-17 inhibitors might reduce the IL-17 dependent SARS-induced cytokine storm. Therefore, IL-17 inhibitorse seem to be safer than TNF-\( \alpha \) for psoriasis during the pandemic.

What do we know about IL-12/IL-23 inhibitors? SARS-CoV-transfected lung cancer cells do not overexpress IL-23 and IL-12p40, and infected dendritic cells had lower expression of IL-12p40 than controls.34,35 Severe SARS-CoV-2 infection leads to increased expression of TNF-\( \alpha \), IL-1, IL-6, and IL-8.36,37 Under these circumstances, IL-12/IL-23 inhibitors do not seem to be beneficial for COVID-19 patients.38 Last but not least, in COVID-19 patients, there is a moderate increase of TNF-\( \alpha \) in severe infections has been observed. This would argue for some benefit of TNF-\( \alpha \) in such patients. Indeed, a randomized, controlled trial of adalimumab for COVID-19 has been registered (ChiCTR2000030089).37

The indication for initiation of systemic drug therapy in psoriasis should be seen more critical during the pandemic. Perhaps, there is a better time to start with the new drugs than just now.27 Similar considerations pertain for patients with moderate-to-severe atopic dermatitis and hidradenitis suppurativa.

The European Task Force on Atopic Dermatitis recommended:

- To continue all immune-modulating treatments, including immune-suppressive therapy, since exacerbations of underlying diseases can have a large negative impact on patient's immunity.
- To strictly follow the recommendations for patients at risk issued by the local health authorities in each European country.
- To carefully observe hygienic procedures using hand wash and disinfectants. Nonirritant soap substitutes should be used in the same way as directed for soap. Moisturizers should be applied afterwards.40

For patients with COVID-19 infection, an interdisciplinary risk assessment is recommended. Considering severity of the disease and comorbidities such as asthma, chronic obstructive lung disease, and other immune-modulating treatment might be continued or paused in accordance with current guidelines on active infections and systemic therapy.40

For Australia and New Zealand, an "immediate withheld" of all immunomodulators, "with the possible exception of corticosteroid therapy" has been recommended for patients with suspected or confirmed COVID-19 infection.27

4 | SYSTEMIC MEDICAL THERAPY FOR INFLAMMATORY SKIN DISEASE

Moderate-to-severe psoriasis can be treated by classical systemic drugs such as methotrexate, ciclosporin A, fumaric esters, and variety of targeted treatments with biologicals and small molecules. Patients suffering from psoriasis arthritis, moderate-to-severe hidradenitis suppurative, or atopic dermatitis benefit from modern systemic treatments as well. Should patients on these drugs interrupt their treatment?

Data are sparse on the subject, but there seems to be consensus that patients with a need for systemic drug therapy and no clinical symptoms of COVID-19 should better continue their treatment instead of risking severe flares. The Australia/New Zealand consensus statement framed: "There is currently insufficient evidence to determine whether dermatology patients on systemic immunomodulators are at increased risk of developing COVID-19 infection or more likely to have severe disease..."27

Systemic corticosteroids are not recommended in acute COVID-19, since doses \( \geq 20 \) mg/ d are immunosuppressive and may prolong the viral shedding.28 Among the biologicals, the theoretical risk of COVID-19 infection seems to be higher with inhibitors of tumor necrosis factor alpha (TNF-\( \alpha \)) compared to interleukin (IL) inhibitors. Among the TNF-\( \alpha \), the risk seems to be somewhat increased with infliximab and its biosimilars. In general, TNF-\( \alpha \) is not recommended during infectious disease.29

Ustekinumab, risankizumab, ixekizumab, and brodalumab do not increase the risk of respiratory infections in general.30,31 However, the data should be interpreted with caution, since we do not have the data for COVID-19 yet. There are reports on drug-induced interstitial lung disease by infliximab, adalimumab, and ustekinumab.32 Patients with preexistent pulmonary problems have a higher risk for COVID-19.

5 | COVID-19 AND THE SKIN CANCER PATIENT

Nonmelanoma skin cancer is the most frequent malignancy. Surgery of primary tumors should not be delayed, in particular in critical
topographical areas, such as perioral, periorcular. Will the limitation of personal protection equipment (PPE) result in a prioritization of cancer and COVID-19 patients?

Malignant melanoma is more aggressive. The best curative treatment is the early complete surgical removal. In case of metastatic disease, systemic treatment has become increasingly effective with a significant prolongation of survival for responders. In patients with metastatic melanoma, treatment delay may result in a loss of the window to treat. For solid tumor patients, "adjuvant therapy with curative intent likely should proceed" according to Ueda et al.43

Palliative care will play a greater role in terminally ill skin cancer patients who may acquire COVID-19 infection, since their chance to survive the infection is minimal even with all available equipment of an ICU.42

6 | TEACHING DERMATOLOGY

Many universities have been closed during the COVID-19 pandemic. Social distancing forbids classical lectures, seminars, and bedside teaching. Digital tools like www.cyberderm.net may offer a way to continue teaching dermatology to students. Teledermatology may temporarily substitute bedside teaching.43

7 | CONCLUSIONS

Dermatology and dermatologists cannot stand off the COVID-19 pandemic. They must be prepared. Dermatologists are important in preventive measures of the health care staff and in the differential diagnosis of generalized rash with fever. Dermatologists need to give advice for patients with severe inflammatory skin disease and systemic drug therapy. Ethical care for advanced skin cancer patients is another challenge. But we are faced to a global problem with a number of unknown facts what does not ease our decisions.44

CONFlict OF INTEREST

The authors declare no potential conflict of interest.

ORCID

Uwe Wollina https://orcid.org/0000-0001-5933-2913

REFERENCES

1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.
2. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1191-1202.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;pii:S0140-6736(20)30566-30563. https://doi.org/10.1016/S0140-6736(20)30566-3.
4. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://coronavirus.jhu.edu/map.html. Assessed April 12, 2020.
5. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies [Article in Chinese]. Zhonghua Bing Li Xue Za Zhi. 2020;49:E009. https://doi.org/10.3767/cma.j.cn112151-2000312-00193.
6. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.
7. Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a ii level hospital. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16386.
8. Kampf G, Todt D, Pfänder S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246-251.
9. Darlenksi R, Tsankov N. Covid-19 pandemic and the skin – what should dermatologists know? Clin Dermatol. 2020. https://doi.org/10.1016/j.clindermatol.2020.03.012.
10. Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Händehygiene in Einrichtungen des Gesundheitswesens. Bundesgesundheitsbl. 2016;59(9):1189-1220.
11. Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther. 2020;e13310. https://doi.org/10.1111/dth.13310.
12. Lan J, Song Z, Miao X, et al. Skin damage among healthcare workers managing coronavirus disease-2019. J Am Acad Dermatol. 2020;pii: S0190-9622(20):30392-30393. https://doi.org/10.1016/j.jaad.2020.03.014.
13. Zheng Y, Lai W. Dermatology staff participate in fight against Covid-19 in China. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16390.
14. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. One more paper towel, longer protection. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.03.064.
15. Wollina U, Hippler U-C, Nenoff P. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19089.
16. Cavanagh G, Wambier C. Rational hand hygiene during COVID-19 pandemic. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.03.090.
17. Bauer A, Rönsch H, Elsner P, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev. 2018;4:CD004414.
18. Jakhar D, Kaur I, Kaul S. Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day! J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16412.
19. Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): An interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6):pii:E1243.
20. Drago F, Ciccarese G, Gasparini G, et al. Contemporary infectious exanthems: an update. Future Microbiol. 2017;12:171-193.
21. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. https://doi.org/10.1111/all.14238.
23. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020. doi.org/10.1111/jdv.16387.

24. Lee C-H. Role of dermatologists in the uprising of the novel coronavirus (COVID-19): perspectives and opportunities. Dermatol Sin. 2020;38(1):1-2.

25. Wollina, U., & Nowak, A. (2012). Dermatology in the intensive care unit. Our Dermatol Online, 3(4), 298–303.

26. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020;41:E006.

27. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement. Australas J Dermatol. 2020. https://doi.org/10.1111/ajd.13313.

28. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.

29. Baysham AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic? J Dermatol Treat. 2020;2:1-2. https://doi.org/10.1080/09546634.2020.1742438.

30. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;50(9-662):20(3):0445-X. https://doi.org/10.1016/j.jaad.2020.03.031.

31. Gordon KB, Strboer B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.

32. Camus, P. (2019). The drug-induced respiratory disease website, Pneumotox Online V2.2. http://www.pneumotox.com. Assessed April 7, 2020.

33. Gurczynski SJ, Moore BB. IL-17 in the lung: the good, the bad, and the ugly. Am J Physiol Lung Cell Mol Physiol. 2018;314(1):L6-L16.

34. Liao HH, Wang YC, Chen MC, et al. Down-regulation of granulocyte-macrophage colony-stimulating factor by 3C-like protease in infected A549 human lung carcinoma cells. BMC Immunol. 2011;12:16.

35. Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366-2374.

36. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa248.

37. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337-342.

38. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013;4(3):e00165-13.

39. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020;13298. https://doi.org/10.1111/dth.13298.

40. Wollenberg A, Flohr C, Simon D, et al. European task force on atopic dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16411.

41. Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020;18:366-369. https://doi.org/10.6004/jnccn.2020.7560.

42. Liang W, Guan W, Ren R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337.

43. Reinholz M, French LE. Medical education and care in dermatology during the SARS-CoV2 pandemic: challenges and chances. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16391.

44. Weston S, Frieman MB. COVID-19: knowns, unknowns, and questions. mSphere. 2020;5(2):e00203-20.

How to cite this article: Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatologic Therapy. 2020;33:13430. https://doi.org/10.1111/dth.13430